Introduction
Are blood, sweat, and saliva merely biological secretions? This article analyzes the evolution of their economic value through the lens of Ruben Verwaal's book The Gift Relationship. You will discover how technology is transforming our bodies into sources of data.
We will trace the trajectory from treating bodily fluids as either gifts or waste to the contemporary bio-economy of data. You will understand why traditional concepts of ownership are insufficient in a world of digital biological analysis and what risks accompany the co-modification of the body.
The Value of Bodily Fluids Depends on Context and Technology
A bodily fluid ceases to be a simple secretion once it is integrated into a system of measurement, processing, or knowledge production. Its value derives not from its chemical composition, but from the intersection of matter, law, and technology.
Sweat serves as a prime example: on a shirt, it is a socially undesirable stain; however, in a biosensor, it becomes a stream of physiological data. This is known as the biological value creation chain, where matter passes through stages of extraction and standardization to become a product or a diagnosis.
This value is dynamic. Urine may be waste that burdens a treatment plant, but through nitrogen recovery technology, it becomes a valuable raw material within a circular economy.
Non-Remunerated Donation Does Not Preclude Commercialization
Although the WHO promotes voluntary and unpaid blood donation, this does not mean the entire system is non-commercial. Only the act of transferring material from the body is free.
Economic value emerges immediately thereafter: in the costly infrastructure, logistics, and the process of plasma fractionation. Material that began as a gift becomes the foundation for highly profitable plasma-derived medicinal products.
This creates a conflict between the model of civic solidarity and economic incentives. There is a risk of crowding out, where payment weakens intrinsic motivation, as well as the danger of exploiting individuals in precarious financial situations.
From Invisible Biological Labor to the Co-Modification of Traits
The value of fluids changes radically when we shift from treating them as biological products to viewing them as information carriers. In sperm banks, one does not sell cells, but rather a set of traits and a genealogical narrative.
This represents a transition to the bio-economy of data. While a physical sample is a finite resource, the data derived from it can be copied at zero cost. Consequently, biobanks store not only matter, but essentially options on future scientific discoveries.
Modern biosensors convert metabolism into biological telemetry. Value shifts from the fluid itself to the interpretive layer: algorithms and predictive models. This creates an information asymmetry where the company controlling the model wields more power than the owner of the body.
Summary
In the digital age, the paradox of the body's permeability has shifted. While the physical invasiveness of measurements is decreasing, the informational penetration of the organism is becoming nearly absolute.
Today, a single drop of fluid can open the door to data that defines our identity for decades. We must move from an extractive model toward responsible custodianship to protect human dignity from being reduced to the role of a raw material supplier for algorithms.
Frequently Asked Questions
When does a body fluid cease to be a secretion and become a valuable economic resource?
A body fluid becomes an economic resource at the moment it ceases to be merely a physiological event and is incorporated into a system of exchange, storage, measurement, processing, or knowledge production. This transformation occurs with the emergence of a tool capable of utilizing a given secretion and the application of collection and standardization procedures.
If blood is donated free of charge, is the entire process of its processing and distribution also non-commercial?
No, the fact that donation is free does not equate to the non-commercial nature of the entire chain. Although the act of transferring biological material remains priceless, costs and economic values arise at subsequent stages, such as testing, transport, or industrial plasma fractionation.
How does the economic value of body fluids change depending on whether we treat them as a biological product or as an information carrier?
Treating body fluids as a biological product involves bodily production costs and procedures for creating a safe clinical product. When treated as an information carrier, the value shifts from the sample itself to data about the donor, transforming the process into a consumer selection of traits and the ability to choose a genealogical scenario.
How does the value of body fluids change during the transition from their physical recovery to digital analysis?
The value of fluids changes from a physical material resource (e.g., recovering elements from urine) to informational value, which lies in the interpretative and analytical layer. While matter is limited and subject to degradation, data obtained from analysis can be copied almost cost-free and may gain new value as technology evolves.
Who owns the rights to biological material and information obtained from patient samples?
There is no universal ownership law for biological material, and regulations vary by country. Instead of full ownership, rights are often divided: the patient may have the right to consent to the use of the sample, the institution the right to store it, and the scientist or inventor the rights to the analysis and the results of their intellectual work.
How do body fluids cease to be treated as matter and become a source of data?
Body fluids become a source of data through the extraction of information such as the genome, proteome, or metabolome, which transforms them into biomarker panels and molecular profiles. Within the bioeconomy of data, the value of these samples increases through their aggregation and the analysis of relationships between them using artificial intelligence algorithms.
How is technology changing the status of body fluids from medical samples into a source of economic data, and who has the right to manage them?
Biosensor technology transforms body fluids into a continuous stream of biological telemetry, which becomes an informational raw material used for market research and product development. The management of this data should be based on a model of responsible custodianship and co-governance systems, including ethical oversight and transparent access rules.
Why is the trade in body fluids not an ordinary market transaction, and what ethical risks are associated with donating a biological sample?
The trade in body fluids differs from ordinary transactions because biological materials are not market products and maintain a permanent reference to the donor even after separation from the body. The main ethical risks include the lack of full autonomy of those selling resources due to poverty and the deepening of social inequalities, where the poor become suppliers and the wealthy become recipients.
How does the value of body fluids change depending on technology, and who should control the benefits derived from them?
The value of body fluids increases with technological development, evolving from waste and resource, through a sample, to data with potentially many times more value than the physical material. The benefits derived from them should be managed under a fair-share model that recognizes the co-creation of value by multiple sources and counteracts the power asymmetry between the donor and the institution.
How can human dignity be protected in a world where body fluids primarily become a source of data?
The key capital of biobanks and medical institutions is public trust, without which people will stop donating biological material. This system relies on the co-production of value by donors and researchers; therefore, it is essential to adhere to the principle prohibiting the reduction of a person to their extractive value.
